Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- PainProstate Cancer
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00005960
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Arena Oncology Associates, Great Neck, New York, United States
🇺🇸Associates of Hematology/Oncology, Upland, Pennsylvania, United States
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
- Conditions
- Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Registration Number
- NCT00005641
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 97
- Registration Number
- NCT00083915
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00003401
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmLeukemiaMyelodysplastic SyndromesLymphoma
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 42
- Registration Number
- NCT00003396
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00003399
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
- Conditions
- Multiple Myeloma
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00083538
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Medical Research Council
- Registration Number
- NCT00002477
- Locations
- 🇬🇧
Cochrane Cancer Network, Oxford, England, United Kingdom
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00002819
- Locations
- 🇺🇸
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Bone Marrow Transplantation in Treating Patients With Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Recombinant Interferon AlfaDrug: CyclophosphamideDrug: EtoposideDrug: MesnaProcedure: Bone Marrow TransplantationRadiation: Radiation Therapy
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00002829
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.